Capricor Therapeutics Shares Soar 250% On Successful COVID-19 Treatment News

Capricor Therapeutics Inc.’s CAPR shares soared after data that pointed to a 100 percent survival rate in critical COVID-19 patients treated with new CAP-1002 cardiac cell therapy was released.

What Happened

Six critically ill COVID-19 patients were treated with CAP-1002, a new cell therapy currently being developed for the treatment of Duchenne muscular dystrophy (DMD). All the patients were treated at Cedars-Sinai Medical Center in Beverly Hills, California, and were suffering from acute respiratory distress syndrome (ARDS). Four of the six patients have now been discharged.

After a review of the available data, the U.S. Food and Drug Administration has approved Capricor’s expanded access protocol to treat up to 20 additional COVID-19 patients with CAP-1002.

Dr. Linda Marbán, the chief executive of Capricor, said in a statement, “CAP-1002 is an easy-to-deliver intravenous therapy that has been administered successfully to over 150 patients to date. Given its novel mechanism of action, it could be a potential game-changer in helping countless COVID-19 patients.”

Why It Matters

The company has reported no adverse effects related to the infusion of CAP-1002 from among the six COVID-19 patients.

Four of the six patients no longer required ventilator support within 1-4 days of receiving the CAP-1002 treatment.

Capricor shares closed more than 250% higher on Wednesday, the same day the treatment data was released. 

The clinical-stage biotechnology company, which had a minuscule market cap of $10.16 million at the beginning of April, was predicted to achieve a triple-digit market capitalization by analysts. At press time, the company’s market cap stood at 101.95 million.

Price Action

Capricor Therapeutics shares traded 3.65% lower at $8.19 in the after-hours session on Wednesday. The shares had closed the regular session 252.70% higher at $8.50.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareMarketsGeneralCoronavirusCovid-19therapy
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!